ライフサイエンスコーパス: phosphodiesterase 5

1 adalafil is a novel long-acting inhibitor of phosphodiesterase-5.

2 Phosphodiesterase 5 activity was measured in lung, vascu

3 S-LTP identified vardenafil and Bay-73-6691 (phosphodiesterase-5 and -9 inhibitors, respectively) as

4 d cGMP, but the isolated first GAF domain of phosphodiesterase 5 binds with K:(d) = 650 nM.

5 ibition of Ca(2+) channel, BK(Ca) channel or phosphodiesterase-5 did not.

6 ism, angiogenesis, adrenergic signaling, and phosphodiesterase-5 expression.

7 tochemical assay confirmed the expression of phosphodiesterase-5 in mouse cardiomyocytes.

8 te mitochondria and that sildenafil-mediated phosphodiesterase 5 inhibition ameliorates dystrophic pa

9 Phosphodiesterase 5 inhibition with sildenafil improves

10 of signaling downstream of endogenous NO by phosphodiesterase-5 inhibition protects against high fat

11 preserved ejection fraction enrolled in the PhosphodiesteRasE-5 Inhibition to Improve CLinical Statu

12 RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Statu

13 The RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Statu

14 h preserved ejection fraction (HFpEF) in the PhosphodiesteRasE-5 Inhibition to Improve Clinical Statu

15 Among patients with HFPEF, phosphodiesterase-5 inhibition with administration of si

16 Phosphodiesterase-5 inhibition with sildenafil compared

17 , therapeutic interventions, such as in vivo phosphodiesterase 5-inhibition, which effectively abroga

18 Here, we report that the phosphodiesterase 5 inhibitor (PDE5) sildenafil (Viagra)

19 The combination of a phosphodiesterase 5 inhibitor and inhaled NO may have cl

20 ric oxide donor sodium nitroprusside and the phosphodiesterase 5 inhibitor sildenafil compared with h

21 This study investigated the effect of the phosphodiesterase 5 inhibitor sildenafil on the pulmonar

22 Sildenafil, an FDA-approved phosphodiesterase 5 inhibitor that enhances NO signaling

23 We tested whether tadalafil, a phosphodiesterase 5 inhibitor used to treat erectile dys

24 ho was receiving treatment with tadalafil, a phosphodiesterase 5 inhibitor, developed bilateral, conc

25 We studied the effects of sildenafil, a phosphodiesterase 5 inhibitor, on coronary and periphera

26 Furthermore, a phosphodiesterase 5 inhibitor, vardenafil, synergizes wi

27 was similar to that in PHIRST, with typical phosphodiesterase-5 inhibitor adverse events.

28 Tadalafil is an oral phosphodiesterase-5 inhibitor approved for PAH treatment

29 candidates for treatment with either an oral phosphodiesterase-5 inhibitor or an oral endothelin-rece

30 onically inhibiting cGMP hydrolysis with the phosphodiesterase-5 inhibitor sildenafil improves energy

31 this study was to assess the effects of the phosphodiesterase-5 inhibitor sildenafil, on I/R injury

32 ts with SCD, administration of sildenafil, a phosphodiesterase-5 inhibitor that potentiates NO-depend

33 therapy and a strong recommendation against phosphodiesterase-5 inhibitor therapy.

34 Previous studies have shown benefits of phosphodiesterase-5 inhibitor treatment for erectile dys

35 designed to evaluate effects of tadalafil, a phosphodiesterase-5 inhibitor used for the treatment of

36 Treatment of mice with the phosphodiesterase-5 inhibitor vardenafil (Levitra) mobil

37 Sildenafil, a phosphodiesterase-5 inhibitor, induces cardioprotection

38 Activation of VASP by the phosphodiesterase-5 inhibitor, sildenafil, in db/db mice

39 The phosphodiesterase-5 inhibitor, sildenafil, potentiates N

40 Endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitors (PDE5I) are long-term the

41 The existence of three phosphodiesterase 5 inhibitors has resulted in an increa

42 We speculate that beneficial effects of phosphodiesterase 5 inhibitors in the systemic vasculatu

43 The use of phosphodiesterase 5 inhibitors is an additional risk fac

44 Early studies showed beneficial effects of phosphodiesterase 5 inhibitors on cardiovascular functio

45 Monotherapy with phosphodiesterase 5 inhibitors seems to be as effective

46 mation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exerc

47 ith SCD, possibly precipitated by the use of phosphodiesterase 5 inhibitors.

48 Phosphodiesterase-5 inhibitors (PDE5Is) improve erectile

49 ered by cinaciguat, riociguat, and different phosphodiesterase-5 inhibitors and beneficial actions of

50 Phosphodiesterase-5 inhibitors are a promising method to

51 promising recent research in treatment with phosphodiesterase-5 inhibitors in single ventricle patie

52 imental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascula

53 Phosphodiesterase-5 inhibitors prevent the breakdown of

54 Phosphodiesterase-5 inhibitors restore NO signaling and

55 rate that the increase of cGMP levels by the phosphodiesterase-5 inhibitors sildenafil and vardenafil

56 erosclerotic ED and a suboptimal response to phosphodiesterase-5 inhibitors were enrolled in this pro

57 lin and its analogs, endothelin antagonists, phosphodiesterase-5 inhibitors, and now a soluble guanyl

58 f ABCG2, such as tyrosine kinase inhibitors, phosphodiesterase-5 inhibitors, and the fumitremorgin-ty

59 ed nitric oxide, sodium nitrite, L-arginine, phosphodiesterase-5 inhibitors, niacin, inhaled carbon m

60 ith prostanoids, endothelin-1 inhibitors and phosphodiesterase-5 inhibitors, or a combination of ther

61 ailable-ie, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclas

62 ysfunction (ED) and a suboptimal response to phosphodiesterase-5 inhibitors.

63 MP/PKG2 signaling, and can be targeted using phosphodiesterase-5 inhibitors.

64 These results show that phosphodiesterase-5 is a potential target for therapies

65 ight benefit cardiovascular diseases because phosphodiesterase-5 is also located elsewhere in the bod

66 ivation and inhibition of the cGMP-degrading phosphodiesterase-5, ischemic preconditioning, and postc

67 ilable for immunohistochemical assessment of phosphodiesterase-5 isoenzyme (PDE-5) and PDE-2 expressi

68 Sildenafil, a potent inhibitor of phosphodiesterase-5 (PDE-5) induces powerful protection

69 We have shown that the potent phosphodiesterase-5 (PDE-5) inhibitor sildenafil (Viagra

70 Phosphodiesterase-5 (PDE-5) inhibitors and endothelin-1

71 Current pharmacologic therapies include phosphodiesterase-5 (PDE-5) inhibitors, such as sildenaf

72 Inhibition of cGMP-specific phosphodiesterase 5 (PDE5) ameliorates pathological card

73 The molecular bases for phosphodiesterase 5 (PDE5) catalytic-site affinity for c

74 Phosphodiesterase 5 (PDE5) controls intracellular levels

75 Phosphodiesterase 5 (PDE5) hydrolyzes cyclic guanosine m

76 Inhibition of phosphodiesterase 5 (PDE5) improves cardiac function in

77 e aim of this work was to test whether acute phosphodiesterase 5 (PDE5) inhibition via sildenafil (SI

78 dystrophin, restoration of nNOS effects by a phosphodiesterase 5 (PDE5) inhibitor (sildenafil) improv

79 Preclinical studies indicate that the phosphodiesterase 5 (PDE5) inhibitor sildenafil is prote

80 Surprisingly, the phosphodiesterase 5 (PDE5) inhibitor sildenafil was foun

81 rse of nitrate interaction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t

82 gated whether sildenafil citrate (Viagra), a phosphodiesterase 5 (PDE5) inhibitor, can be used to ame

83 Addition of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, in the drinking wa

84 iptional modulation by sildenafil, a popular phosphodiesterase 5 (PDE5) inhibitor.

85 udies determined whether clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with cl

86 Phosphodiesterase 5 (PDE5) inhibitors limit myocardial i

87 tivation and CXCL13 induction are blocked by phosphodiesterase 5 (PDE5) inhibitors.

88 by the chronic inhibition of cGMP-selective phosphodiesterase 5 (PDE5) suppressed maladaptive cardia

89 Substrate binding to the phosphodiesterase-5 (PDE5) catalytic site increases cGMP

90 Phosphodiesterase-5 (PDE5) contains a catalytic domain (

91 Here we report that phosphodiesterase-5 (PDE5) gene expression and PDE activ

92 Recently, targeting cyclic-GMP specific phosphodiesterase-5 (PDE5) has attracted much interest i

93 oth muscle cells (PASMCs), and inhibition of phosphodiesterase-5 (PDE5) has been shown to suppress TR

94 of vardenafil, a potent and highly selective phosphodiesterase-5 (PDE5) inhibitor, on symptom-limited

95 Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadal

96 Phosphodiesterase-5 (PDE5) inhibitors and other agents t

97 Phosphodiesterase-5 (PDE5) inhibitors improve exercise c

98 Phosphodiesterase-5 (PDE5) inhibitors increase intracell

99 Phosphodiesterase-5 (PDE5) inhibitors promote nitric oxi

100 The activity of phosphodiesterase-5 (PDE5) is specific for cGMP and is r

101 Phosphodiesterase-5 (PDE5) is the target for sildenafil,

102 Vardenafil has higher affinity to phosphodiesterase-5 (PDE5) than sildenafil and lower adm

103 peting with this nucleotide for catalysis by phosphodiesterase-5 (PDE5), but the characteristics of d

104 ach competitively inhibit cGMP hydrolysis by phosphodiesterase-5 (PDE5), thereby fostering cGMP accum

105 Sildenafil inhibits phosphodiesterase 5 (PDE5A) to elevate intracellular cGM

106 d by cGMP-dependent allosteric activation of phosphodiesterase 5, which shapes the amplitude and dura